Avantor (AVTR) shares closed at $15.67 after recent trading, attracting attention as investors weigh mixed return figures over the past year against longer term declines and the company’s latest revenue and earnings profile.
Avantor’s recent 1 day share price return of 1.82% comes after a 30 day share price return of 5.81% and a strong 90 day move of 38.80%, yet the 5 year total shareholder return is down 59.36%, which signals short term momentum against a much weaker long term record.
Scan how Avantor’s recent rebound compares with other lab supplies and life sciences tools players by running the curated list of solid balance sheet and fundamentals (25 results) alongside this stock’s profile.
Avantor’s rebound has pulled the share price slightly above the average analyst target, while internal fair value estimates still point to a discount. Is this move already fully priced in, or is there still value on the table?
Most Popular Narrative: 7.6% Overvalued
Avantor’s last close at $15.67 sits above the most followed fair value estimate of $14.56. This frames the recent rebound as richer than the central narrative suggests and puts more pressure on the turnaround plan to justify that gap over time.
The numbers and current valuation together imply a stock price that already reflects a fair outcome where Avantor delivers on its multi year turnaround and free cash flow targets without needing a sharp re rating from here.
The focus now is on internal Revival actions, digital execution and backlog conversion as the primary drivers for revenue and earnings.
See why 10 investors see Avantor as 8% overvalued.
Result: Fair Value of $14.56 (OVERVALUED)
Still, if competitive pressure in lab distribution persists or if weakness across biotech and academic funding drags on, Avantor’s Revival plan could deliver less than analysts currently build in.
Find out about the key risks to this Avantor narrative.
Another View On Avantor’s Valuation
While the analyst based fair value of $14.56 paints Avantor as 7.6% overvalued, Simply Wall St’s DCF model points the other way, with a future cash flow value of $17.25 and the current $15.67 price at a discount. Which framework do you think better matches the Revival execution risk?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed signals on Avantor’s valuation and turnaround plan can feel messy. Move quickly, review the same numbers, then weigh the 3 key rewards and 1 important warning sign.
Looking For More Investment Ideas Beyond Avantor?
If Avantor has you thinking more carefully about valuation and risk, do not stop here. Use a broader set of ideas to pressure test your next move.
- Target steadier potential by reviewing companies that score well on financial strength through the list of solid balance sheet and fundamentals (25 results).
- Hunt for mispriced opportunities by scanning the 29 high quality undervalued stocks that combine quality fundamentals with pricing that trails underlying business performance.
- Press for resilience by focusing on companies with stronger downside protection using the 31 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com